辰欣药业
(603367)
| 流通市值：105.17亿 | | | 总市值：105.17亿 |
| 流通股本：4.53亿 | | | 总股本：4.53亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,739,772,668.35 | 920,204,017.65 | 3,981,572,232.95 | 3,002,250,189.03 |
| 营业收入 | 1,739,772,668.35 | 920,204,017.65 | 3,981,572,232.95 | 3,002,250,189.03 |
| 二、营业总成本 | 1,493,369,715.45 | 741,656,866.42 | 3,483,462,580.81 | 2,615,901,369.99 |
| 营业成本 | 762,686,922.36 | 370,718,292.66 | 1,729,094,050.53 | 1,285,236,267.21 |
| 税金及附加 | 21,718,986.97 | 11,884,592.12 | 48,830,120.32 | 36,479,943.59 |
| 销售费用 | 442,378,641.95 | 227,815,118.85 | 1,093,997,243.75 | 820,785,390.01 |
| 管理费用 | 132,659,889.27 | 63,297,807.13 | 301,383,573.72 | 224,841,086.04 |
| 研发费用 | 145,961,598.45 | 73,643,696.38 | 342,641,077.12 | 272,306,294.13 |
| 财务费用 | -12,036,323.55 | -5,702,640.72 | -32,483,484.63 | -23,747,610.99 |
| 其中:利息费用 | 644,994.95 | 232,645.31 | 6,946,102.2 | 5,684,632.21 |
| 其中:利息收入 | 13,997,902.78 | 6,458,310.27 | 39,569,027.81 | 28,654,750.81 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 20,859,960.15 | 5,340,389.94 | 10,528,296.23 | 24,844,374.41 |
| 加:投资收益 | 34,665,215.33 | 27,630,033.95 | 62,304,296.38 | 23,637,115.57 |
| 资产处置收益 | 419,694.25 | 434,730.77 | -139,530.24 | 13,294.63 |
| 资产减值损失(新) | -44,149,228.19 | -42,046,125.66 | -56,025,858.73 | -39,585,051.66 |
| 信用减值损失(新) | -13,402,505.99 | -13,397,494.28 | 4,163,418.64 | -5,285,220.61 |
| 其他收益 | 11,938,487.17 | 3,850,265.59 | 53,107,499.08 | 45,839,852.59 |
| 四、营业利润 | 256,734,575.62 | 160,358,951.54 | 572,047,773.5 | 435,813,183.97 |
| 加:营业外收入 | 854,929.51 | 471,481.27 | 4,897,731.64 | 3,928,523.8 |
| 减:营业外支出 | 1,139,332.25 | 808,855.25 | 1,172,145.71 | 799,249.41 |
| 五、利润总额 | 256,450,172.88 | 160,021,577.56 | 575,773,359.43 | 438,942,458.36 |
| 减:所得税费用 | 25,161,941.17 | 15,409,975.26 | 60,832,924.8 | 35,590,147.65 |
| 六、净利润 | 231,288,231.71 | 144,611,602.3 | 514,940,434.63 | 403,352,310.71 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 231,288,231.71 | 144,611,602.3 | 514,940,434.63 | 403,352,310.71 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 229,150,905.93 | 143,544,555.3 | 508,906,193.71 | 398,119,097.94 |
| 少数股东损益 | 2,137,325.78 | 1,067,047 | 6,034,240.92 | 5,233,212.77 |
| 扣除非经常损益后的净利润 | 179,657,826.73 | 116,201,160.43 | 425,905,281.67 | 363,457,971.02 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.51 | 0.32 | 1.12 | 0.88 |
| (二)稀释每股收益 | 0.51 | 0.32 | 1.12 | 0.88 |
| 八、其他综合收益 | 455,209.39 | 455,209.39 | -21,088.5 | -656,483.48 |
| 归属于母公司股东的其他综合收益 | 455,209.39 | 455,209.39 | -21,088.5 | -656,483.48 |
| 九、综合收益总额 | 231,743,441.1 | 145,066,811.69 | 514,919,346.13 | 402,695,827.23 |
| 归属于母公司股东的综合收益总额 | 229,606,115.32 | 143,999,764.69 | 508,885,105.21 | 397,462,614.46 |
| 归属于少数股东的综合收益总额 | 2,137,325.78 | 1,067,047 | 6,034,240.92 | 5,233,212.77 |
| 公告日期 | 2025-08-28 | 2025-04-22 | 2025-04-22 | 2024-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |